The Olympic Games in 1908 Paris

,C.D.C. Recommends 2 Covid Vaccines for under 5s ONS, https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/antibodies 95.9% of children aged 8 to 11 years had antibodies against SARS-CoV-2 Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children Risks of Myocarditis and Pericarditis The FDA and CDC safety surveillance systems have previously identified increased risks of myocarditis and pericarditis following vaccination with the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, particularly following the second dose. The observed risk is highest in, males 18 through 24 years of age for the Moderna males 12 through 17 years of age for the Pfizer-BioNTech COVID-19 Vaccine. most cases of myocarditis associated with the Moderna and Pfizer-BioNTech COVID-19 vaccines are characterized by rapid resolution of symptoms with no impact on quality of life reported by most patients who were contacted for follow-up at 90 days or more after reporting myocarditis. https://www.nytimes.com/live/2022/06/18/world/covid-19-mandates-vaccine-cases 19 million Moderna for ages 6 months through 5 years Pfizer-BioNTech ages 6 months through 4 years Dr. Rochelle P. Walensky, the C.D.C.’s director All children 6 months and older, including those who have already been infected with the coronavirus, should get a Covid vaccine Together, with science leading the charge, we have taken another important step forward in our nation’s fight against Covid-19 We know millions of parents and caregivers are eager to get their young children vaccinated, and with today’s decision, they can Albert Bourla, Chairman and Chief Executive Officer, Pfizer We know many parents in the U.S. have been eagerly awaiting an authorized vaccine for their children under 5 and we are proud to now offer them a vaccine option with a favorable safety profile Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune Vaccine efficacy was 80.3% in children 6 months to under 5 years of age. N = 1,678 had 3 doses, (omicron times) This descriptive analysis was based on 10 symptomatic COVID-19 cases identified from seven days after the third dose and accrued as of April 29, 2022. (3 in the vaccine group, 7 in the placebo group) The trial protocol specifies a formal analysis will be performed when at least 21 cases have accrued from seven days after the third dose. Final vaccine efficacy data will be shared once available. Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use MODERNA ANNOUNCES ITS COVID-19 VACCINE PHASE 2/3 STUDY IN CHILDREN 6 MONTHS TO UNDER 6 YEARS HAS SUCCESSFULLY MET ITS PRIMARY ENDPOINT https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx 6 months to 2 years, n = 2,500 enrolled 2 to under 6, n = 4,200 enrolled Rates of fever post vaccine, greater than 38 6 months to 2 years, 17% 2 years to under 6, 14.6% 6 to 12 years, 23.9% Vaccine efficacy Similar antibody response to in 18- to 25-year-olds 6 months to 2 years, 43.7% 2 to under 6 years, 37.5% Kaiser Family Foundation survey https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-april-2022/ Plan to get under 5s vaccinated, 18% Definitely not, 27% Tom Inglesby, Johns Hopkins Center for Health Security, Bloomberg School of Public Health There’s a lot of information and trust building that needs to happen Hopefully, with time, people will have increasing confidence that it’s both effective and safe Neither vaccine was tested against BA.4 and BA.5 (exceptional immune escape) Peter Hotez, molecular virologist, National School of Tropical Medicine at Baylor College of Medicine, Houston The pediatric vaccines, won’t hold up that well in protecting against infection by the new subvariants But they will still be very effective in preventing children from going to the hospital or the intensive care unit ACIP Committee Members https://www.cdc.gov/vaccines/acip/members/index.html

00:02:26

Lerp infestation raises concerns about fire hazards in Scripps Ranch

more_vert

CBS 8 San Diego check_circle

1K views 3 years ago

01:26

The Olympic Games in 1908 Paris

more_vert

Question Everything check_circle

1 views 2 years ago

00:41:07

LLaMA: Open and Efficient Foundation Language Models (Paper Explained)

more_vert

Yannic Kilcher check_circle

92K views 3 years ago

,#ai #meta #languagemodel LLaMA is a series of large language models from 7B to 65B parameters, trained by Meta AI. They train for longer on more data and show that something like gpt-3 can be outperformed by significantly smaller models when trained like this. Meta also releases the trained models to the research community. OUTLINE: 0:00 - Introduction & Paper Overview 4:30 - Rant on Open-Sourcing 8:05 - Training Data 12:40 - Training Hyperparameters 14:50 - Architecture Modifications 17:10 - Optimizer 19:40 - Efficient Implementation 26:15 - Main Results 38:00 - Some more completions 40:00 - Conclusion Paper: https://arxiv.org/abs/2302.13971 Website: https://ai.facebook.com/blog/large-language-model-llama-meta-ai/ Abstract: We introduce LLaMA, a collection of foundation language models ranging from 7B to 65B parameters. We train our models on trillions of tokens, and show that it is possible to train state-of-the-art models using publicly available datasets exclusively, without resorting to proprietary and inaccessible datasets. In particular, LLaMA-13B outperforms GPT-3 (175B) on most benchmarks, and LLaMA-65B is competitive with the best models, Chinchilla-70B and PaLM-540B. We release all our models to the research community. Authors: Hugo Touvron, Thibaut Lavril, Gautier Izacard, Xavier Martinet, Marie-Anne Lachaux, Timothée Lacroix, Baptiste Rozière, Naman Goyal, Eric Hambro, Faisal Azhar, Aurelien Rodriguez, Armand Joulin, Edouard Grave, Guillaume Lample Links: Homepage: https://ykilcher.com Merch: https://ykilcher.com/merch YouTube: https://www.youtube.com/c/yannickilcher Twitter: https://twitter.com/ykilcher Discord: https://ykilcher.com/discord LinkedIn: https://www.linkedin.com/in/ykilcher If you want to support me, the best thing to do is to share out the content :) If you want to support me financially (completely optional and voluntary, but a lot of people have asked for this): SubscribeStar: https://www.subscribestar.com/yannickilcher Patreon: https://www.patreon.com/yannickilcher Bitcoin (BTC): bc1q49lsw3q325tr58ygf8sudx2dqfguclvngvy2cq Ethereum (ETH): 0x7ad3513E3B8f66799f507Aa7874b1B0eBC7F85e2 Litecoin (LTC): LQW2TRyKYetVC8WjFkhpPhtpbDM4Vw7r9m Monero (XMR): 4ACL8AGrEo5hAir8A9CeVrW8pEauWvnp1WnSDZxW7tziCDLhZAGsgzhRQABDnFy8yuM9fWJDviJPHKRjV4FWt19CJZN9D4n

00:06:59

Bert Kreicher and Tom Segura Get Classy | The Roast of Tom Brady | Netflix Is A Joke

more_vert

Netflix Is A Joke check_circle

420K views 2 years ago